维普期刊资源整合服务平台（V6.5）

406篇 您的检索式：作者名="Talpaz"

选中清除导出查看参考文献查看引证文献引用追踪共21页首页上一页第1页下一页末页 /21 跳转

	题名	作者	年代	出处	被引量
1	Dasatinib用于治疗对伊马替尼耐药的Ph染色体阳性白血病显示文摘	Talpaz M Shah NP Kantarjian H 菅鑫妍	2006	中国处方药2006，5，8：	12
2	Physiology and pathophysiology of dendritic cells 显示文摘	Mcclain KL Talpaz M	1997	Hum Pathol1997，28，5：	1
3	Phase Ⅰ safety and pharmacokinetic study of recombinat human antivascular endothelial growth factor in patients with advanced cancer 显示文摘	Gordon MS Margolin K Talpaz M	2001	J Clin Oncol2001，19，4：	1
4	Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia-comparison with historic experience显示文摘	Kantarjian HM Talpaz M O' Brien S	2005	Cancer2005，103，10：	1
5	Dasatinib in imatinib-resistant philadelphia chromosome-positive leukemias 显示文摘	TALPAZ M SHAH N P KANTARJIAN H	2006	New Eng JMed2006，354，24：	1
6	Chronic myeloid leukemia:Changing the treatment paradigms显示文摘	Savona M Talpaz M	2006	Oncology( Williston Park)2006，20，7：	1
7	Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia显示文摘	Talpaz M Resta D	2001	N Engl J Med2001，344，：	1
8	Serum beta-2microglobulin levels are a significant prognostic factor inPhiladelphia chromosome-positive chronic myelogenousleukemia显示文摘	Rodriguez J Cortes J Talpaz M	2000	Clin Cancer Res2000，6，1：	1
9	Dasatinib(BMS-3548285)tyrosine kinase inhibitor suppresses invasion andinduces cell cycle arrest and apoptosis of head and necksquamous cell carcinoma and non-small cell lung cancercells显示文摘	Johnson FM Saigal B Talpaz M	2005	Clin Cancer Res2005，11，191：	1
10	New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance显示文摘	KANTARJIAN H M TALPAZ M GILES F	2006	Ann Intern Med2006，145，：	1
11	The biology of chronic myeloid leukemia 显示文摘	Faded S Talpaz M Estrov V	1999	New Engl J Mede1999，165，3：	1
12	The role of interferon-alpha in the treatment of chronic myeloid leukemia 显示文摘	Kujawski LA Talpaz M	2007	Cytokine Growth Factor Rev2007，18，56：	1
13	Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate显示文摘	Talpaz M O'Brien S	2005	Clin Cancer Res2005，11，9：	1
14	The biology of chronic myeloid leukemia显示文摘	FADERL S TALPAZ M ESTROV Z	1999	N Engl J Med1999，341，3：	1
15	High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosomepositive chronic myeloid leukemia显示文摘	Kantarjian H Talpaz M O'Brien S	2004	Blood2004，103，：	1
16	Pilot study of SCH66336 (Lonafarnib),a farnesyl transferase inhibitor (FTI),in patients with chronic myeloid leukemia (CML) in chronic or accelerated phase resistant or refractory to imatinib显示文摘	Cortes JE Daley G Talpaz M	2002	Blood2002，100，：	1
17	Serum beta -2 mieroglobulin levels are a significant prognostic factor in Philadelphia positive chronic myelo - genous leukemia 显示文摘	Rodriguez J Cortes J Talpaz M	2000	Clin Cancer Res2000，6，：	1
18	Efficacy and safety of a specific inhibitor of the BCR -ABL tyrosine kinase in chronic myeloid leukemia 显示文摘	Druker B J Talpaz M Resta D J	2001	N En gl J Med2001，344，：	1
19	Phase Ⅰ safety and pharmacokintic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer显示文摘	Gorden MS Margolin K Talpaz M	2001	J Clin Oncol2001，19，：	1
20	The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase 显示文摘	SNEED T B KANTARJIAN H M TALPAZ M	2004	Cancer2004，100，：	1

返回顶部每页显示：

共21页首页上一页第1页下一页末页 /21 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示